These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38716791)

  • 1. Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
    Mazagatos C; Mendioroz J; Rumayor MB; Gallardo García V; Álvarez Río V; Cebollada Gracia AD; Batalla Rebollo N; Barranco Boada MI; Pérez-Martínez O; Lameiras Azevedo AS; López González-Coviella N; Castrillejo D; Fernández Ibáñez A; Giménez Duran J; Ramírez Córcoles C; Ramos Marín V; Larrauri A; Monge S;
    Influenza Other Respir Viruses; 2024 May; 18(5):e13294. PubMed ID: 38716791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Ares-Gómez S; Mallah N; Santiago-Pérez MI; Pardo-Seco J; Pérez-Martínez O; Otero-Barrós MT; Suárez-Gaiche N; Kramer R; Jin J; Platero-Alonso L; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Piñeiro-Sotelo M; Malvar-Pintos A; González-Pérez JM; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F;
    Lancet Infect Dis; 2024 Aug; 24(8):817-828. PubMed ID: 38701823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
    López-Lacort M; Muñoz-Quiles C; Mira-Iglesias A; López-Labrador FX; Mengual-Chuliá B; Fernández-García C; Carballido-Fernández M; Pineda-Caplliure A; Mollar-Maseres J; Shalabi Benavent M; Sanz-Herrero F; Zornoza-Moreno M; Pérez-Martín JJ; Alfayate-Miguelez S; Pérez Crespo R; Bastida Sánchez E; Menasalvas-Ruiz AI; Téllez-González MC; Esquiva Soto S; Del Toro Saravia C; Sanz-Muñoz I; Eiros JM; Matías Del Pozo V; Toquero-Asensi M; Pastor-Villalba E; Lluch-Rodrigo JA; Díez-Domingo J; Orrico-Sánchez A
    Euro Surveill; 2024 Feb; 29(6):. PubMed ID: 38333937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
    Griffin MP; Yuan Y; Takas T; Domachowske JB; Madhi SA; Manzoni P; Simões EAF; Esser MT; Khan AA; Dubovsky F; Villafana T; DeVincenzo JP;
    N Engl J Med; 2020 Jul; 383(5):415-425. PubMed ID: 32726528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
    Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
    BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
    Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS
    MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nirsevimab and Hospitalization for RSV Bronchiolitis.
    Assad Z; Romain AS; Aupiais C; Shum M; Schrimpf C; Lorrot M; Corvol H; Prevost B; Ferrandiz C; Giolito A; Valtuille Z; Bendavid M; Cohen JF; Toubiana J; de Pontual L; Delande CF; Levy M; See P; Cohen R; Levy C; Angoulvant F; Lenglart L; Gits-Muselli M; Biran V; Diallo K; Alemede O; El Hebil MM; Durrmeyer X; Labouret G; Casanovas N; Hallak B; Maréchal O; Jung C; Bréhin C; Ouldali N
    N Engl J Med; 2024 Jul; 391(2):144-154. PubMed ID: 38986058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM
    Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19.
    Subissi L; Bossuyt N; Reynders M; Gérard M; Dauby N; Bourgeois M; Delaere B; Quoilin S; Van Gucht S; Thomas I; Barbezange C
    Euro Surveill; 2020 Oct; 25(39):. PubMed ID: 33006303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.
    Agüera M; Soler-Garcia A; Alejandre C; Moussalam-Merino S; Sala-Castellví P; Pons G; Penela-Sánchez D; González-Grado C; Alsina-Rossell J; Climent C; Esteva C; Fortuny C; de-Sevilla MF; García-García JJ; Brotons P; Balaguer A; Estrada J; Jordan I; Muñoz-Almagro C; Launes C
    Pediatr Allergy Immunol; 2024 Jun; 35(6):e14175. PubMed ID: 38899631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.
    Paireau J; Durand C; Raimbault S; Cazaubon J; Mortamet G; Viriot D; Milesi C; Daudens-Vaysse E; Ploin D; Tessier S; Vanel N; Chappert JL; Levieux K; Ollivier R; Daoudi J; Coignard B; Leteurtre S; Parent-du-Châtelet I; Vaux S
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13311. PubMed ID: 38840301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validity of laboratory-based surveillance for detection of respiratory syncytial virus seasons.
    Hampp C; Asal N; Lipowski E; Kauf T; Schneider E; Kubilis P; Winterstein A
    Am J Epidemiol; 2013 Apr; 177(8):841-51. PubMed ID: 23479344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
    Domachowske JB; Chang Y; Atanasova V; Cabañas F; Furuno K; Nguyen KA; Banu I; Kubiak RJ; Leach A; Mankad VS; Shroff M; Takas T; Villafana T; Wählby Hamrén U
    J Pediatric Infect Dis Soc; 2023 Aug; 12(8):477-480. PubMed ID: 37466917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resurgence of Respiratory Syncytial Virus in Children: An Out-of-Season Epidemic in Portugal.
    Torres AR; Guiomar RG; Verdasca N; Melo A; Rodrigues AP;
    Acta Med Port; 2023 May; 36(5):343-352. PubMed ID: 36705636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.